Stock info Zealand Pharma | Filter  Basic-Info

Zealand Pharma

The company's head quarter is located in Glostrup (Copenhagen). Over the past 10 years the global pharmaceutical companies gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year was a profitable year for Zealand Pharma investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Zealand Pharma, the stock lost around 24 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 77 percent. Zealand Pharma's revenues between 2011 and 2015 were very constant and moved between 29,98 million euros and 25,15 million euros. Zealand Pharma's net results between 2011 and 2015 were very fluctuating and moved between 1,89 million euros and -15,27 million euros.

The Danish company didn't pay out any dividends (in the past 5 years).

Zealand Pharma financed with a quite low debt position

At the end of 2015 the Danish company had a balance sheet of 85,05 million euros. Of the total balance sheet 51,25 million euros (60,26 percent) was financed by debt. As per the end of 2015 Zealand Pharma's price/earnings-ratio equaled -129. So investors paid for 1 stock -129 times the earnings per share of 2015. We could say that based on her price/earnings-ratio and dividend yield the Danish stock can be seen as a growth stock.

At the end of 2015 the Danish company's market capitalization equaled around 3,61 billion euros. At the end of 2015 the Danish company had around 23,64 million stocks listed on the stock exchange(s).

All of Zealand Pharma's annual reports are stored here. More information about Zealand Pharma can be found it's website. .